A novel second line chemotherapy treatment of recurrent thymoma

• Published in: Medical oncology (Northwood, London, England) Vol. 14; no. 3-4; pp. 163 - 168
• Main Authors: JAN, N, VILLANI, G. M, TRAMBERT, J, FEHMIAN, C, SOOD, B, WIERNIK, P. H
• Format: Journal Article
• Language: English
• Published: Heidelberg Springer 01-09-1997; Springer Nature B.V
• Subjects: Adult; Antineoplastic agents; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Carboplatin - administration & dosage; Chemotherapy; Humans; Male; Medical sciences; Neoplasm Metastasis; Neoplasm Recurrence, Local - drug therapy; Oncology; Paclitaxel - administration & dosage; Pharmacology. Drug treatments; Thymoma - drug therapy; Thymus Neoplasms - drug therapy; Antineoplastic agent; Human; Drug combination; Thymoma; Mediastinum disease; Male; Thymus pathology; Case study; Chemotherapy; Treatment; Taxane derivatives; Paclitaxel; Carboplatin; Tumor; Advanced stage; Platinum II Complexes
• ISSN: 1357-0560; 1559-131X
• DOI: 10.1007/bf02989645

Thymoma is an uncommon malignancy which is initially treated with surgery. Combined modality treatment with radiation and chemotherapy is utilized in cases of unresectable or metastatic disease. In patients with relapse, a number of different chemotherapeutic regimens have been used with varying success. The case of a male with recurrent thymoma treated with carboplatin and paclitaxel is presented and the literature reviewed. The patient responded to this novel regimen with improvement in clinical symptoms and reduction in tumor mass. This novel regimen has shown activity as second line therapy and merits further investigation as a first line treatment for patients with invasive and or metastatic thymoma.